Abstract

There is a paradox offered up by the cancer stem cell hypothesis. How are the mixed populations that are characteristic of heterogeneous solid tumors maintained at constant proportion, given their high, and different, mitotic indices? In this study, we evaluate a well-characterized mouse model of human basaloid tumors (induced by the oncogene Wnt1), which comprise mixed populations of mammary epithelial cells resembling their normal basal and luminal counterparts. We show that these cell types are substantially inter-dependent, since the MMTV LTR drives expression of Wnt1 ligand in luminal cells, whereas the functional Wnt1-responsive receptor (Lrp5) is expressed by basal cells, and both molecules are necessary for tumor growth. There is a robust tumor initiating activity (tumor stem cell) in the basal cell population, which is associated with the ability to differentiate into luminal and basal cells, to regenerate the oncogenic paracrine signaling cell pair. However, we found an additional tumor stem cell activity in the luminal cell population. Knowing that tumors depend upon Wnt1-Lrp5, we hypothesized that this stem cell must express Lrp5, and found that indeed, all the stem cell activity could be retrieved from the Lrp5-positive cell population. Interestingly, this reflects post-transcriptional acquisition of Lrp5 protein expression in luminal cells. Furthermore, this plasticity of molecular expression is reflected in plasticity of cell fate determination. Thus, in vitro, Wnt1-expressing luminal cells retro-differentiate to basal cell types, and in vivo, tumors initiated with pure luminal cells reconstitute a robust basal cell subpopulation that is indistinguishable from the populations initiated by pure basal cells. We propose this is an important proof of concept, demonstrating that bipotential tumor stem cells are essential in tumors where oncogenic ligand-receptor pairs are separated into different cell types, and suggesting that Wnt-induced molecular and fate plasticity can close paracrine loops that are usually separated into distinct cell types.

Highlights

  • There are various potential explanations for the cellular heterogeneity that exists in some tumors

  • Using a mouse model of basaloid tumors, we have noticed that differentiation to basal and luminal cell fates is important to the establishment of an oncogenic paracrine cell pair, and propose that this may be true for human breast cancer patients

  • Bipotential stem cells are required to create optimal proportions of basal and luminal cells, to promote the growth of tumors that depend upon a paracrine interaction. This is a proof of concept that we propose could offer a discovery platform for therapeutic development, assuming that co-mingling of basal and luminal cell types could have functional significance for human basaloid tumors

Read more

Summary

Introduction

There are various potential explanations for the cellular heterogeneity that exists in some tumors. Heterogeneity could reflect random allocation to different cell fates, or be the result of uncontrolled growth of a tumor stem cell, if that tumor stem cell is a normal stem cell ‘‘gone bad’’ [1] In this scenario (given differentiation is not suppressed), the diversity of cell types existing in the tissue of origin could be recapitulated in the tumor. Human and mouse basaloid breast tumors are characterized by the over-representation of mRNA species typically associated with basal cells in transcriptional profiles (for example, cytokeratins 5/ 6/14/17, TRIM29 and collagen type XVII) This often, but not always, correlates with the so-called ‘‘triple negative’’ status (ERa-, PR- and erbB2-negative) [2,3,4]. They contain mammary epithelial cell types that resemble their basal and luminal cell counterparts in normal mammary gland, and are illustrated in tumor sections using immunohistochemistry [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call